Accessibility Menu
NeurAxis logo

NeurAxis(NYSEMKT) NRXS

Market Cap$85.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)+15%
5 YearN/A
1 Year+161%
1 Month-11%
$6.28
-8.59%
-0.59Today
After hours$6.22-$0.06 (-0.96%)
NeurAxis last closing stock price
MetricPriceDate
Last closeUSD 6.352026-08-11
NeurAxis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.42%USD 7.012026-08-04
1 month-11.06%USD 7.142026-07-10
3 month-19.72%USD 7.912026-05-13
Year to date+39.87%USD 4.542025-12-31
1 year+161.32%USD 2.432025-08-11
3 year+3.25%USD 6.152023-08-11
Since inception+14.5%USD 6.002023-08-09

NeurAxis Financials at a Glance

Market Cap

$85.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.28M

Net Income (TTM)

-$7.28M

EPS (TTM)

-$0.81

P/E Ratio

-8.43

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$6.28

Volume

395,145.154

Open

$6.05

Previous Close

$6.35

Daily Range

$5.50 - $6.78

52-Week Range

$2.20 - $9.33

Estimated Earnings Date

Aug 11, 2026

NRXS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NeurAxis

NeurAxis makes medical devices for children and adults with stomach pain. Its main product helps young patients manage abdominal pain from irritable bowel syndrome. Hospitals and clinics use these devices to improve patient comfort and reduce symptoms.

Products and Services

  • IB-Stim: Wearable device for children and teens with abdominal pain from irritable bowel syndrome; used in hospitals and clinics.
  • RED Device: Diagnostic tool for adults with chronic constipation; launched in 2025, revenue share not yet disclosed.
  • NSS-2 Bridge: Device for opioid withdrawal symptoms; rights recaptured in July 2025 after license ended.
  • NeuroStim (EAD): Electroacupuncture device, now used only for research purposes.
  • Training & Support: Provider training, patient advocacy, and financial assistance programs for device access.

Growth and Expansion

  • Launched RED device for adult constipation diagnostics in 2025.
  • Expanded IB-Stim indications with new FDA clearance in 2025.
  • Secured Federal Supply Schedule contract for U.S. government sales in December 2025.
  • Broadened clinical trials to new conditions like post-concussion and fibromyalgia pain.
  • Increased direct sales force and insurance outreach ahead of new reimbursement code in 2026.

What Makes NeurAxis Stand Out

NeurAxis is the only company with an FDA-cleared device for pediatric abdominal pain from irritable bowel syndrome. Its products are recommended in leading pediatric guidelines and supported by published clinical studies. The company holds a strong patent portfolio and focuses on U.S. children’s hospitals.

Five Things You Need to Know

  • Net sales were $3.57 million in 2025, up 32.9% from 2024.
  • Gross margin declined to 84.2% in 2025, down from 86.5% in 2024.
  • Operating loss was $7.83 million in 2025, up 9.4% from 2024.
  • Cash and equivalents were $5.0 million at year-end 2025.

Bottom Line

NeurAxis has grown by focusing on pediatric pain devices and expanding into adult diagnostics. The company faces ongoing losses but continues to develop new products and clinical uses.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

24

CEO

Brian Carrico

Website

www.neuraxis.com

Headquarters

Carmel, IN 46032, US

NRXS Financials

Key Financial Metrics (TTM)

Gross Margin

85.01%

Operating Margin

-169.93%

Net Income Margin

-170.11%

Return on Equity

-185.74%

Return on Capital

-205.19%

Return on Assets

-83.28%

Earnings Yield

-11.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$85.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.48M

Volume

395.15K

Avg. Volume

102.60K

Financials (TTM)

Gross Profit

$3.64M

Operating Income

-$7.28M

EBITDA

-$7.12M

Operating Cash Flow

-$6.06M

Capital Expenditure

-$13.15K

Free Cash Flow

-$6.07M

Cash & ST Invst.

$7.08M

Total Debt

$353.52K

NeurAxis Performance Analysis

NeurAxis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,684,735-1.3%
20232023-12-31USD 2,460,049-8.4%
20242024-12-31USD 2,685,9259.2%
20252025-12-31USD 3,569,28232.9%
NeurAxis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-0.2%
Q32025-09-30-9.2%
Q42025-12-3119.3%
Q12026-03-3166.1%
NeurAxis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.9046.8%
20232023-12-31USD -2.25148.8%
20242024-12-31USD -1.22-45.6%
20252025-12-31USD -0.95-22.4%
NeurAxis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3033.3%
Q32025-09-30-9.1%
Q42025-12-3133.3%
Q12026-03-31-12.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.61M

+79.5%

Gross Profit

$1.39M

+83.8%

Gross Margin

86.42%

N/A

Market Cap

$85.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.57M

N/A

Employees

24

N/A

Net Income

-$1.76M

+22.7%

EBITDA

-$1.72M

+24.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.08M

+253.0%

Total Debt

$353.52K

-9.1%

Accounts Receivable

$385.01K

+58.0%

Inventory

$238.28K

+536.8%

Long Term Debt

$184.00K

-22.9%

Short Term Debt

$169.52K

+12.9%

Return on Assets

-83.28%

N/A

Return on Invested Capital

-1.23%

N/A

Free Cash Flow

-$1.23M

+24.2%

Operating Cash Flow

-$1.23M

+23.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RLYBRallybio Corporation
$16.38-1.38%
ENLVEnlivex Therapeutics Ltd.
$1.92-4.48%
TAOXTAO Synergies Inc.
$3.62+3.72%
NRSNNeuroSense Therapeutics Ltd.
$0.47-2.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$97.71+0.00%
SPCXSpace Exploration Technologies
$133.29-0.04%
NVDANvidia
$217.50-0.00%
SMCISuper Micro Computer
$31.60+0.00%

Questions About NRXS

What is the current price of NeurAxis?

NeurAxis is trading at $6.35 per share.

What is the 52-week range for NeurAxis?

Over the past 52 weeks, NeurAxis has traded between $2.20 and $9.33.

How much debt does NeurAxis have?

As of the most recent reporting period, NeurAxis reported total debt of $353.52K.

How much cash does NeurAxis have on hand?

NeurAxis reported $7.08M in cash and cash equivalents in its most recent financial results.

What is NeurAxis’s dividend yield?

NeurAxis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services